Life Sciences Alternative Funding

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

VisionCare Ophthalmic Technologies, Inc., a Saratoga, CA-based developer of advanced visual prosthetic devices designed to improve vision in patients with end-stage age-related macular degeneration (AMD). VisionCare Ophthalmic Technologies (VisionCare) is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. The telescope implant is integral to the CentraSight™ treatment program which has been developed to help patients follow the necessary steps for proper diagnosis, surgical evaluation, and postoperative care. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.